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 ABSTRACT 
SAVANNAH FAIRLEY: Synthesis of (2R,6R)- Hydroxynorketamine for Evaluation 
of Antidepressant Effects  
(Under the direction of Dr. John Rimoldi) 
Major Depressive Disorder, colloquially known as depression, is a devastating 
mental illness that affects a large portion of today’s population. Following a drug 
side-effect that caused depression, the monoamine theory of depression was created, 
stating that depressive symptoms were caused by a decrease in concentrations of vital 
monoamine neurotransmitters at the synaptic cleft. Pharmaceutical remedies to 
combat depression were first introduced in the 1950s and to this date, most available 
drugs follow the monoamine theory. These drugs have a large loading dose lag time, 
numerous negative side effects, and still many patients do not experience relief from 
symptoms.   In 2000, the Stress-neurogenic theory was proposed, suggesting 
depressive symptoms decreased neurogenesis and dendritic retraction, induced by 
excess cortisol from chronic stress. This new theory opened the door for further 
studies to be conducted on possible pharmacotherapies for MDD.  Ketamine had 
shown some antidepressant effects, but was not a sufficient option due to the 
dissociative effects and history of abuse. Further studies were done to indicate that 
ketamine’s antidepressant effects were caused by the metabolite (2R,6R)-
hydroxynorketamine and that the mechanism of action seems to be NMDA receptor 
independent. The goal of this thesis was to construct an efficient complete synthesis 
pathway of (2R,6R)- hydroxynorketamine from commercially available chemicals. 
This was done by evaluating chemically and structurally similar reactions that had 
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been previously published to piece together a new synthesis of (2R,6R)-HNK. The 
product of this research will be sent to a partnering lab for further studies to be 
completed on the NMDA-independent and possibly AMPA receptor-dependent 
mechanism by which ketamine exhibits such promising antidepressant effects.  
Further understanding of this mechanism brings us one step closer to better future 
pharmacotherapies for MDD. 
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Introduction 
 
Morbidity of Major Depressive Disorder 
 Major Depressive Disorder (MDD), more commonly known as depression, is a 
mental illness that is both chronic and debilitating, with a very high morbidity.1 It is 
related to the natural emotion of sadness but does not remit once the external cause 
dissipates.2 According to the 5th edition of the Diagnostic and Statistical Manual of 
Mental Disorders, MDD is characterized by an individual exhibiting at least five of the 
outlined depressive symptoms every day for a minimum of two weeks. These five 
symptoms may include: changes in appetite or weight, slowing of speech and action, 
disturbance of sleep schedule, strong feeling of worthlessness, lack of concentration, and 
suicidal ideation or actions.1,2  MDD has a life time prevalence of 14.4%, making it the 
most common mood disorder and the second most common mental illness in the United 
States, second to anxiety.1 MDD has major socioeconomic consequences.  Due to the 
combination of high morbidity rates and debilitating symptoms, MDD places a huge 
burden on the economy, contributing to $83.1 billion in healthcare expenses in the United 
States (Year 2000 statistics).1   On average, workers that suffer from severe depressive 
symptoms missed 13.7 more hours and cost their employers almost twice the healthcare 
expenses per year compared to other workers.1 
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History of MDD Treatments and Theories 
 There are several FDA approved therapies indicated for the treatment of MDD; 
however, they have several key disadvantages that limit their effectiveness. In addition to 
unwanted side effects, the pharmaceutical drugs designed to treat MDD have a delayed 
onset of about 4-12 weeks before any measurable remission of symptoms are noticed.1 
Even after this time period, some patients never experience therapeutic relief, despite 
taking escalating doses. Those that fit into this category are considered to have treatment 
resistant depression and they account for 34-46% of all MDD diagnosed patients.1 
 All of the FDA approved drugs indicated for the treatment of MDD are based on 
the monoamine theory of depression, which claims that MDD patients have low 
concentrations of serotonin, norepinephrine, and dopamine.  Regardless of the therapeutic 
class, all aim to produce an increase in the concentration of these monoamine 
neurotransmitters at synaptic clefts. Evidence for the monoamine theory for depression 
was based on the drug reserpine, used in the 1950s to treat hypertensive vascular disease.  
Patients taking reserpine appeared to develop depression that remissed once the drug 
therapy was terminated. Studies confirmed the findings that reserpine inhibited a 
vesicular monoamine transporter and therefore lowered the concentrations of 
monoamines in the brain.1 Another proof for the monoamine theory came from studies 
using monoamine oxidase inhibitors (MAOIs).  MAOIs target and inhibit the enzyme 
monoamine oxidase, an enzyme responsible for the metabolism and clearance of 
neurotransmitter amines, resulting in the increase in concentration of these 
neurotransmitters.   New therapeutics began to emerge with incremental advances in their 
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pharmacological mechanisms of action, but with the same end result: they were designed 
to increase concentrations of monoamine neurotransmitters at the neuronal synapses in 
order to alleviate depressive symptoms.1 
 The next therapeutic class of drugs discovered after the MAOIs was the tricyclic 
inhibitors of norepinephrine and serotonin. Drugs in this class inhibit presynaptic 
norepinephrine and serotonin reuptake transporters as well as block postsynaptic 
adrenergic alpha receptors, postsynaptic muscarinic receptors, and postsynaptic histamine 
receptors.1 The inhibition of these reuptake transporters for both norepinephrine and 
serotonin are cited to be the reason for the remission of symptoms, keeping in line with 
the monoamine theory of depression. 
 Major advances in treating depression was realized with the discovery of the 
selective serotonin reuptake inhibitors (SSRIs), which prevent the reuptake of serotonin 
resulting in clinically relevant increases in concentrations in the synaptic cleft and a 
higher concentration available to stimulate serotonin receptors at post-synaptic receptors. 
Logically, serotonin-norepinephrine inhibitors (SNRIs) were developed, therapeutics able 
to target both serotonin and norepinephrine reuptake receptors, but are more selective 
than the tricyclic drugs.  
 
Figure I.  Summarized selective serotonin reuptake inhibitor mechanism of action.6 
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These are just a few of the current MDD therapeutic classes that are FDA 
approved Despite the variety in drug design and pharmacological mechanisms of actions, 
all of the current drugs for MDD require a loading dose lag time before they are effective. 
In addition, there are many treatment resistant MDD patients, which presents a need for 
further research.  
 
 
Figure II. Summary of Major Classes of Antidepressant Drugs.7 
 
 
The Stress-Neurogenic Theory  
 Due to the large number of patients suffering from treatment resistant depression, 
there is support that depletion of monoamines may be a side effect of a much larger 
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neurobiological system in play.1 The shortcomings of current MDD treatments led 
researchers to develop a new theory: the stress-neurogenic theory of depression. This 
theory states that unpredicted or chronic stress causes a larger amount of stress hormones 
to be produced, which in turn induce neuronal damage in areas of the brain, such as the 
amygdala and the hippocampus. Stress causes the release of corticotrophin-releasing 
hormone (CRH) from the hypothalamus that induces the release of corticotrophin from 
the pituitary gland.1 Corticotrophin then activates the adrenal gland to release cortisol, 
which in excess causes decreased neurogenesis and dendritic retraction, leaving the 
neurons vulnerable to neurotoxicity and other metabolic changes.3 With this proposed 
theory, research efforts have been redirected to finding novel treatment pathways. 
 
History of Ketamine and its Use as an Antidepressant  
 The FDA approved ketamine in 1970 as a short-term, noncompetitive NMDA 
receptor antagonist anesthetic in humans and animals, however it did not become widely 
used until the Vietnam War. Due to its light and controllable dissociative effects, 
ketamine’s role in pediatric and veterinary medicine grew rapidly, as did its popularity as 
a recreational street drug. Recently, ketamine has been associated with antidepressant 
effects. The administration of sub-anesthetic doses of ketamine to MDD patients has 
shown strong and persistent efficacy, even within the first hour of the first dose.4 
Although these findings bring great excitement to the field and to treatment resistant 
patients, this drug has limitations due to its hallucinogenic and dissociative effects as well 
as its abuse liability.4 For this reason, research efforts have focused on the identification 
of ketamine’s direct antidepressant mechanism.  
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 In vivo pharmacology studies have demonstrated that the N-demethylated 
metabolite norketamine exhibited approximately 50% of the anesthetic effects of 
ketamine, while hydroxynorketamine (HNK) had no anesthetic effects at all.5 This led 
researchers to hypothesize that norketamine was the active agent of ketamine and that its 
clinical effects came from N-methyl-D-aspartate receptor (NMDAR) inhibition.4 These 
studies led to the conclusion that hydroxynorketamine was therefore inactive.5  
 
 
Figure III. Structure of Ketamine and two of its metabolites 
 
More recent studies have investigated the concurrence of the antidepressant 
effects and the inhibition at the NMDA receptors, and have proved that other NDMA 
antagonists do not produce similar antidepressant effects.4 This data indicates that 
ketamine’s antidepressant effects are likely due to an NMDAR inhibition- independent 
mechanism. Additional studies were performed to specifically test hydroxyl-
norketamine’s antidepressant effects. Ketamine was altered so that its metabolites, 
(2S,6S; 2R,6R)-hydroxynorketaine (HNK) would not form, however, the pharmacological 
effects of the molecule were not affected. Studies showed that without (2S,6S or 2R,6R)-
HNK, antidepressant effects were not observed.4 It was confirmed that the  (2R,6R)-HNK 
enantiomer exhibited the most efficacy in antidepressant trials, which also negates the 
NMDAR hypothesis since the S-HNK enantiomer is a more potent NMDAR inhibitor.4 
Cl
O
NH
H3C
Ketamine
Cl
O
NH2
Cl
O
NH2 OH
Norketamine (2R,6R)-Hydroxy-norketamine (HNK)
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During trials, a single dose of (2R,6R)-HNK exhibited antidepressant effects similar to 
those of ketamine; fast and persistent remission of symptoms.4  
To further assess the mechanism of action of  (2R,6R)-HNK, researchers used 
tagged molecules bound at NMDA receptors to measure the metabolites antagonistic 
effect.  In the vitro studies, (2R,6R)-HNK did not displace the tagged molecules, 
therefore the antidepressant effects of (2R,6R)-HNK are not associated with the NMDA 
receptors.4 However, the metabolite did show an increase in α- amino-3-hydroxy-5-
methyl-4-isoxazolepropionic acid (AMPA) receptor mediated excitatory post-synaptic 
potentials as well as an increase in the frequency and amplitude of AMPAR-mediated 
excitatory postsynaptic currents.4 Studies confirmed the role of AMPA receptor 
activation on antidepressant effects. Mice were pretreated with an AMPAR antagonist 
prior to (2R,6R)-HNK injections, resulting in no noticeable antidepressant effects. This 
indicated that activation of the AMPA receptors is required for (2R,6R)-HNK 
antidepressant mechanism of action.4 
Ketamine’s use as an antidepressant drug is limited due to the abuse liability and 
the sensory, motor, and dissociative effects it causes. Studies prove that (2R,6R)-HNK 
did not produce any sizable changes in motor and sensory process, even at high doses.4 
Due to the lack of side effects and the NMDAR- independent mechanism of action; 
(2R,6R)-HNK is a favorable molecule for the development of new, fast-acting 
antidepressant drug treatments. The goal of this study was to develop a novel and 
efficient complete synthesis of (2R,6R)-hydroxynorketamine to be used for in vivo 
physiological studies.  
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Results and Discussion 
As a result of several milestone publications, it is now well-established that 
the ketamine metabolite, (2R,6R)-hydroxynorketamine is a major contributor to 
ketamine’s antidepressant effects. The specific aim of the thesis research outlined was 
to design and execute a simple and cost-effective synthesis of (2R,6R)-
hydroxynorketamine (HNK). This compound will be tested in the laboratory of Dr. 
Kenneth Sufka at the University of Mississippi using an innovative and unique in 
vivo antidepressant screening model.  This laboratory has developed and continues to 
validate an avian social-separation stress procedure that simulates several 
characteristics of treatment-resistant depression (TRD).13 Indeed, it is the only assay 
that meets the FDA definition of TRD, which is the failure to respond to two classes 
of FDA-approved antidepressants.14,15 If this model successfully screens HNK, this 
may very well open the door to the development and screening of a broad library of 
compounds related to HNK that may prove highly efficacious in TRD populations. 
The design of synthetic pathways for this project began in Spring 2017; at this 
time there were no synthetic reports published for (2R,6R)-hydroxynorketamine.  
Since then, two total synthesis have been reported.  Researchers at the Experimental 
Therapeutics and Pathophysiology Branch, National Institute of Mental Health, NIH 
reported the synthesis of  (2R,6R)-hydroxynorketamine from (R)-ketamine (prepared 
in 6 steps from cyclohexanone) using a Rubottom oxidation as the key step in the 
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synthesis, providing a 72% yield and an excellent diastereomeric ratio to 
install the α-keto-alcohol with the desired stereochemistry (Figure 4). 8 
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Figure IV.  Morris Synthesis, NIDA-NIH, 2017.8 
 
A second synthesis of (2R,6R)-hydroxynorketamine was reported by Corey, 
who utilized a mechanistically-guided catalyst selection (manganese) for the initial 
olefin epoxidation step, and a novel O → N displacement with retention of 
configuration through the use of Al- or Ti-based azides to promote epoxide activation 
and internal cis delivery of azide (Figure 5).  Although novel and elegant, the 
synthesis is expensive due principally to the use of a chiral Mn catalyst and non-
commercially available reagents.9 
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Figure V.  Corey Synthesis, Harvard, 2017 9 
 
One theme emerges from the analysis of the reported syntheses: they both 
invoke the synthesis of (R)-norketamine (or its protected version) followed by a late-
stage oxidation. Although these two papers described the successful synthesis of 
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(2R,6R)-HNK, the goal of this thesis research was to design a new and 
efficient synthesis, cost-effective and scalable.  Our synthesis began with easily 
accessible and commercially available starting materials, with the initial aim of 
synthesizing gram scale racemic norketamine.  The racemic material would then be 
subject to diastereomeric salt formation for enantiomer resolution.   Figure VI 
illustrates the synthetic pathways employed.  
 
 
Figure VI: Synthesis of (rac)-Norketamine (7a).  Experimental Conditions:  a.) Mg, 
THF, chlorobromobenzene, 1, (40%). b.) PTSA, toluene, reflux (92%); c.) NaHCO3 
(15mL) NaHCO3, m-CPBA, (80%); d.) HBr (aq.), PCC, CHCl3 (39%). e.) DMSO, 
NaN3 (82%).  f.)   PPh3, water, reflux. 
Cl
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The synthesis of racemic norketamine (7) was initially reported by Sulake et 
al.  We adopted this methodology, apart from the use of deuterium labeled reagents 
and made some improvements to the reported methods.  Commercially available 
bromo-chlorobenzene was converted to a Grignard reagent and reacted with 
cyclohexanone (1) to yield the tertiary alcohol (2), which was subject to a dehydration 
step affording olefin (3) in good yields.  The low yielding Grignard reaction may be a 
consequence of moisture present during the reaction.  This step was not optimized.   
The stage was set for an epoxidation reaction of 3 with m-CPBA; initial experiment 
confirmed the findings that the epoxide generated was relatively unstable. A change 
in the Rf value was noticed after the compound had been stored for a week at 0°C.  
Therefore, the epoxidation was performed using a biphasic solution of 
dichloromethane and 5% sodium bicarbonate to eliminate the potential for 
rearrangement products, resulting in epoxide 4.8   The epoxide ring was then subjected 
to regioselective epoxide ring-opening reaction with HBr followed by a PCC-
mediated oxidation to yield the targeted brominated ketone (5) in a one-pot reaction. 
Compound 5 was then treated with  sodium azide to afford product 6.   A Staudinger 
reaction was employed for the reduction of azide (6) to generate (rac)-norketamine 7.   
The mechanism of this reaction involves the reaction of triphenyphosphine with the 
terminal nitrogen of the azide, followed by a facile rearrangement, leading to the 
intermediate iminophosphorane.  Water attack on this intermediate leads to a 
hydrolytic reaction generating amine and triphenylphosphine oxide as the by-product 
(which is not easily separated from the product). 
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Figure VII:  Proposed Staudinger Reaction Mechanism. 10 
 
 A quantity of (rac)-norketamine (7) has been successfully synthesized, and 
prior to enantiomeric resolution using a chiral salt, initial experiments were conducted 
to explore a simple and cost effective late stage oxidation reaction.  Reaction of 7 
with methychloroformate afforded carbamate 8.  Reactions are in progress to explore 
the scope and utility of a new and simple oxidation reaction that has been recently 
reported, namely the DMSO-Iodine promoted direct oxidation of carbonyl 
derivatives.  The simple and readily available iodine or NBS is used as catalyst, and 
DMSO acts as the oxidant, oxygen source, and solvent.11 The interpretation of the 
mechanism is that the oxidation should proceed from the less hindered face of the 
cyclohexone ring, and facial selectivity should be improved by the directing effects of 
the amine carbamate group.  If this reaction proves successful, the remaining steps are 
to conduct a deprotection reaction of the carbamate (KOH hydrolysis), and resolution 
of the major cis-disasteromer. 
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Figure VIII: Final Protection-Oxidation-Deprotection Steps.	    
Cl
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Materials and Methods 
General Methods 
 All reactions were completed using commercially available solvents and 
reagents. Every reaction was done under standard anhydrous conditions, unless 
otherwise stated. Standard anhydrous conditions meaning that oven-dried glassware 
was purged with argon in order to remove all moisture and anhydrous “dry” solvents 
were used.  All reactions were monitored with thin layer chromatography (TLC) to 
check amount of starting material leftover and for product formation. 
Phosphomolybdic acid was used to stain all TLC plates, as it had the best results for 
these compounds. Low-resolution mass spectroscopy was obtained at each step to 
confirm that the product molecular weight was present.  For all Nuclear Magnetic 
Resonance (NMR) data, a Bruker 400 MHz Avance NMR spectrometer was used, 
and all raw data was processed with MestReNova software.  
 
(2)  1-(2-chlorophenyl)cyclohexan-1-ol 
 A Grignard reagent was created by adding a solution of o-
bromochlorobenzene (2.2 mL) in dry THF (22 mL) drop wise to a mixture of Mg (0.5 
g) and I2 (cat.) in anhydrous THF (8 mL) at 10-15 °C over 0.5 h. A solution of 
cyclohexanone (2.29 mL) in dry THF (15 mL) was added to the Grignard reagent at 
0°C and stirred for 1 h. The temperature was then slowly increased to 20-25°C and 
the reaction continued to stir for 15 h. The mixture was quenched with sat. NH4Cl, 
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added dropwise. The mixture was then extracted with an equal amount of EtOAc and 
the organic layer was washed with brine, dried over Na2SO4 , and concentrated under 
reduced pressure to give a yellow oil. The product was purified by silica gel column 
chromatography (hexane/EtOAc, 10:1). This reaction yielded 1.59 g (40%) of 2. (1H 
NMR (400 MHz, Chloroform-D) δ 7.72 – 7.45 (m, 1H), 7.40 – 6.91 (m, 3H), 2.49 (d, 
J = 22.7 Hz, 1H), 2.27 – 2.02 (m, 2H), 2.01 – 1.42 (m,7H), 1.41– 1.05 (m, 1H),	  13C 
NMR (101 MHz, CDCl3) δ 144.96, 131.67, 128.15, 127.25, 127.01, 77.35, 77.04, 
76.72, 73.91, 35.63, 25.34, 21.94. 
 
(3)  1-(2-chlorophenyl)cyclohexene 
 Compound 2 (1.59 g) was dissolved in toluene (32 mL) and dehydrated by 
refluxing with PTSA (75 mg) and using azeotropic distillation by way of a Dean-
Stark   condenser. The mixture refluxed for 3 hours at 160°C and then left to stir at 
room temperature for 12h. The reaction mixture was washed with saturated NaHCO3 
and water. The organic layer was dried over Na2SO4 and then concentrated under 
pressure to give 1.34 g (92%) as a colorless oil. (1H NMR (400 MHz, Chloroform-D) 
δ 7.43 – 7.24 (m,2H), 7.26 – 7.14 (m, 4H), 5.70 (s,1H), 5.65 (s, 1H), 2.33 (td, J = 5.9, 
2.8 Hz, 3H), 2.22 (tt, J = 7.1, 3.6 Hz, 3H), 2.18 (s, 3H), 1.85 – 1.69 (m, 7H), 13C 
NMR (101 MHz, CDCl3) δ 143.48, 137.67,132.45, 130.17, 129.47, 127.71, 127.25, 
126.55, 100.00, 77.35, 77.03, 76.71, 29.15, 25.40, 22.88, 22.0
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(4) 1-(2-chlorophenyl)-7-oxabicyclo[4.1.0]heptane 
 A solution of 5% NaHCO3 (15 mL) was added to m-CPBA (1.48 g, 8.6 mmol) 
in DCM (15 mL) and stirred and 0°C. Compound 3 was dissolved in DCM (3 mL) 
and added dropwise to this solution, which was then stirred for 15 h at room 
temperature. The reaction mixture was separated using H2O, dried over Na2SO4. The 
compound was purified with silica gel chromatography (hexane/EtOAc, 10:1) to yield 
1.32 g (80%) colorless oil. (1H NMR (400 MHz, Chloroform-D) δ 7.46 (dd, J =7.2, 
2.0 Hz, 1H), 7.43 – 7.31 (m, 1H), 7.30 – 7.17 (m, 2H), 2.08 (ddq, J = 30.1, 14.7, 8.7, 
7.3 Hz, 3H), 1.68 – 1.39 (m, 3H), 13C NMR (101 MHz, CDCl3) δ 141.23, 132.10, 
128.96, 128.53, 127.99, 126.78, 100.00, 77.35, 77.04, 76.72, 60.58, 60.02, 29.43, 
24.78, 20.31, 18.80).  
 
(5) 2-bromo-2-(2-chlorophenyl)cyclohexanone 
 Compound 4 (1.32 g, 6.35 mmol) was dissolved in chloroform (30 mL) and 
stirred with 48% aq. hydrobromic acid (17 mL) at 0°C for 0.5 h. The aqueous layer 
was separated and then extracted three times with chloroform (3x 10 mL). The 
combined organic layer was then washed with equal amounts of sat. aq. NaHCO3. 
The solvent was evaporated off and the residue was redissolved in DCM (20 mL). 
Pyridinium chlorochromate was added to this solution and stirred at RT for 13h. The 
reaction mixture was filtered through celite and then washed with HCl and water. 
Organic layer was washed with water and brine and then dried over Na2SO4. The 
product was concentrated under pressure and then purified using silica gel 
chromatography (hexane/EtOAc, 10:1) to yield 700 mg (39%) of a colorless oil. (1H 
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NMR (400 MHz, Chloroform-D) δ 7.99 (d, J =7.4 Hz, 1H), 7.37 (ddq, J = 24.3, 16.3, 
8.8, 8.1 Hz, 4H), 3.09 (dd, J = 15.3, 8.4 Hz, 1H), 3.00 – 2.90 (m,1H), 2.65 (d, J = 15.4 
Hz, 1H), 2.41 (d, J = 15.1 Hz, 1H), 1.95 – 1.89 (m, 1H), 13C NMR (101 MHz, 
CDCl3) δ 201.43, 170.66, 137.86, 131.89, 131.34, 130.96, 129.71, 127.37, 77.35, 
77.03, 76.71, 73.55, 43.09, 37.38, 25.56, 22.63. 
 
 
(6) 2-azido-2-(2-chlorophenyl) cyclohexanone 
 DMSO (3.67mL) was used to create a solution of compound 5 (700mg). NaN3 
(468mg) was added to the DMSO solution and stirred at 25°C for 5 h. The reaction 
mixture was combined with water (10mL) and extracted with ethyl acetate (10mL x 
3). The organic layer was then washed with water and then dried over Na2SO4. The 
compound was purified using silica gel chromatography (hexane/EtOAc, 10:1) and 
gave 500mg (82%) as a colorless oil. (1H NMR (400 MHz, Chloroform-d) δ 7.47 
7.26 (m,1H), 2.75 – 2.47 (m, 1H), 2.07 – 1.95 (m, 1H), 1.86 (ddddd, J = 27.6, 18.9, 
14.0, 8.3, 4.3 Hz, 1H), 13C NMR (101 MHz, CDCl3) δ 203.26, 137.13, 132.46, 
131.35, 129.67, 127.95, 127.35, 77.34, 77.03, 76.71, 74.05, 38.86, 37.58, 25.41, 
21.31). 
 
(7) 2-amino-2-(2-chlorophenyl) cyclohexanone 
 Triphenylphosphine (600mg) was added to a solution of THF (10mL) and 
compound 6 (500mg). This mixture refluxed for 12 h at 65°C, water (0.15mL) was 
added and the mixture continued to reflux for 3 h. The solvent was removed under 
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pressure and the compound was diluted with DCM (7mL) and 1M HCl (7mL). Sat. 
NaHCO3 was used to basify the aqueous layer, which was then extracted with DCM 
(3 x 10mL). The organic layer was washed with water and dried over Na2SO4. The 
compound was concentrated under pressure to yield a colorless oil. (1H NMR (400 
MHz, Chloroform-d) δ 7.80 – 7.73 (m, 3H), 7.72 – 7.62 (m, 25H), 7.59 – 7.51 (m, 
16H), 7.51– 7.40 (m, 28H), 7.40 – 7.35 (m, 4H), 7.35 – 7.27 (m,4H), 3.32 (s, 1H), 
2.62 – 2.57 (m, 1H), 2.02 (s, 1H), 1.84 – 1.74 (m, 4H), 1.26 (s, 4H), 13C NMR (101 
MHz, CDCl3) δ 170.66, 132.96, 132.14, 132.04, 131.99, 131.96, 131.92, 131.20, 
129.95, 128.58, 128.55, 128.46, 127.51, 77.40, 77.08, 76.76, 38.92, 29.70, 22.00). 
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